European Commission Approves OPUVIZ™ (SB15), a Biosimilar to Eylea, for Treatment of Retinal Disorders

Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) announced that the European Commission (EC) has approved OPUVIZ™ 40 mg/mL solution...

November 19, 2024 | Tuesday | News
Rona Therapeutics’ RN0191 Demonstrates Significant LDL-C Reduction in Phase 1 Trial

Rona Therapeutics, a leader in innovative RNA-based therapies, presented positive results from the Phase 1 clinical trial of RN0191 at the American Heart A...

November 18, 2024 | Monday | News
Arcturus Therapeutics Receives FDA Green Light for Clinical Trial of sa-mRNA Vaccine Targeting Pandemic H5N1 Influenza

Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a commercial messenger RNA medicines company focus...

November 12, 2024 | Tuesday | News
Health Canada Approves Moderna’s mRESVIA™ RSV Vaccine for Adults 60 and Older

Moderna, Inc. (NASDAQ:MRNA) announced Health Canada has approved mRESVIA™ (Respiratory Syncytial Virus mRNA vaccine) for active immunization for the ...

November 11, 2024 | Monday | News
Ardena Expands Bioanalytical Services with New Lab in Oss, Netherlands, Enhancing Capabilities to Meet Growing Client Demand

  Ardena, a specialist pharmaceutical Contract Development and Manufacturing Organisation (CDMO) with GMP facilities in Belgium, Spain, the Netherlan...

October 31, 2024 | Thursday | News
AstraZeneca’s Fasenra Receives EU Approval as Add-On Treatment for Eosinophilic Granulomatosis with Polyangiitis

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing ...

October 29, 2024 | Tuesday | News
GSK Announces Promising Data for Arexvy Vaccine in Younger Adults at Risk for RSV

GSK plc (LSE/NYSE: GSK) announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at inc...

October 25, 2024 | Friday | News
Pfizer Expands Pneumococcal Vaccine Recommendations for Adults 50 and Older Following CDC Advisory Committee Vote

Pfizer Inc. (NYSE: PFE) announced that the U.S. Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practice (ACIP)...

October 24, 2024 | Thursday | News
Sanofi and CD&R Announce Exclusive Negotiations for 50% Stake in Opella, Poised to Create Global Consumer Healthcare Leader

 Sanofi and CD&R announce a plan to join forces to fuel Opella’s ambitions as a French-headquartered, global consumer healthcare champion. S...

October 22, 2024 | Tuesday | News
Merck Presents Promising Phase 3 Results for CAPVAXIVE™ Vaccine at IDWeek 2024

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced results from STRIDE-8, a Phase 3 trial evaluating CAPVAXIVE™ (Pneu...

October 17, 2024 | Thursday | News
Americans Victor Ambros and Gary Ruvkun Win Nobel Prize in Medicine for Landmark Discovery of microRNA

The Nobel Prize in Physiology or Medicine has been awarded to American researchers Victor Ambros and Gary Ruvkun for their pioneering discovery of microR...

October 07, 2024 | Monday | News
Renaissance Lakewood Begins U.S. Manufacturing of FDA-Approved neffy®, the First Needle-Free Epinephrine Nasal Spray for Anaphylaxis

Renaissance Lakewood, LLC (“Renaissance”), a leading global contract development and manufacturing organization (“CDMO”) is proud...

October 04, 2024 | Friday | News
Recipharm and Exela Pharma Forge Strategic Alliance to Boost U.S. Sterile Manufacturing with 100+ Million Units Capacity

Sterile manufacturing capability in the US with over 100 million readily-available units (including vials and Pre-Filled Syringes – PFS) Extensi...

October 04, 2024 | Friday | News
European Commission Poised to Authorize Omicron KP.2-Adapted COVID-19 Vaccine for Individuals Aged 6 Months and Older

Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and o...

September 23, 2024 | Monday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close